A new meta-analysis suggests that pathological complete response should not be used as a surrogate endpoint in randomized trials of neoadjuvant therapies for early breast cancer.
Reuters Health Information
Home Breast Cancer Pathological Complete Response Likely Not a Reliable Survival Surrogate in Early Breast...
Pathological Complete Response Likely Not a Reliable Survival Surrogate in Early Breast Cancer
